ALZHEIMER’S RESEARCH UK: THREE HIGHLIGHTS FROM A YEAR OF PROGRESS
By Hilary Evans-Newton | Monday 03 November 2025
Our Annual Report for 2024/25 is now live, and each year it reminds me to pause and reflect on how far we’ve come. We’ve entered a new era for dementia research and although we have a lot of work to do before we reach a cure, there is a lot to celebrate and look forward to.
We’re incredibly grateful to everyone who helped us achieve a record-breaking income, showing just how strongly people believe in our mission to speed up progress towards a cure.
1. More research funded than ever before
Thanks to everyone who helped to raise funds, we were able to commit £30.8 million to life-changing dementia research, the most in our history. That funding supported over 3,200 dedicated researchers and led to 530 scientific publications; each one sharing a new discovery about how to detect, prevent, treat, and one day cure the diseases that cause dementia.
In diagnosis, we saw the first NHS trial of a blood test for Alzheimer’s begin, part of the £5m Blood Biomarker Challenge. The study gained a lot of attention with over 5,000 people signing up for updates.
We’re also uncovering more ways to prevent dementia. We co-funded the Lancet Commission on Dementia Prevention, Intervention, and Care, which identified two new risk factors: uncorrected vision loss and high cholesterol.
2. Our supporters are driving us closer to a cure
From extreme fundraising challenges to sharing experiences in media, our supporters have once again shown incredible commitment, standing shoulder to shoulder with us to stop dementia.
Our flagship Walk For A Cure event returned for a second year, raising over £284,000. That’s over 3,500 hours of research.
Our Corporate Partnerships continue to inspire action. We welcomed back Omaze, whose collaboration with actor Brian Cox CBE, helping to raise nearly £4 million pounds. While the moving film ‘Memory’ from Cadbury continues to poignantly illustrate the emotion of loving someone with dementia.
3. Our voice is influencing change
After decades of research, the first effective treatments that slow Alzheimer’s – lecanemab and donanemab – were licensed in the UK. Unfortunately, the medicines were not approved for use on the NHS. This marked a bittersweet moment for all of us who have been working towards new treatments. And we called on the Government to work with industry and others to improve access to new treatments and diagnostic services.
Through our powerful media presence in over 13,500 news stories, we kept dementia research a national priority. When the government launched plans for a new 10-year Health Plan for England, we ensured the voices of people affected by dementia were heard.
Our campaign film Together. For A Cure. Now. voiced by actor Stephen Graham, brought their message to life, reminding viewers at home why research needs all of us if we’re to bring about a cure.
Explore the shorter Annual Review.
Check out the Alzheimer’s Research UK RIA Foundation Member profile here .